BETA
Your AI-Trained Oncology Knowledge Connection!
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Case 3: A 49-Year-Old with R/R MM Treated with Bispecifics and Develops Adenoviral Infection
An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.
Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Managing Toxicities in Patients With MM Treated with ASCT or Novel Therapies
Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.
The Importance of Access to Care for Multiple Myeloma in Community Settings
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Expanding the Treatment Armamentarium in RRMM with Novel Therapies
Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.
Trials Focused on ctDNA in Colorectal Cancer
An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.
Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.
CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
Using ‘Intensity’ to Gain ‘Deep Control’ in Myeloma at Ohio State
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
BiTE Therapy May Impact Standard of Care in Multiple Myeloma, Expert Says
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Triplet and Quadruplet Therapy Options for Patients With Transplant-Eligible NDMM
An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.
Future Directions in mHSPC Management: An Evolving Treatment Landscape
Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.
Patient Profile 1: A 61-Year-Old with Transplant-Eligible Newly Diagnosed MM
A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.
Transplant Eligibility in Patients With NDMM
Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.
The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment
Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.
Unmet Needs in Diffuse Large B-Cell Lymphoma
Andre H. Goy, MD, and Andrew Ip, MD, offer closing remarks on unmet needs in the treatment of diffuse large B-cell lymphoma.
Efficacy of Immunotherapies for dMMR or MMRp Advanced/Recurrent Endometrial Cancer
The panel discusses their opinions on the use of immunotherapy in different populations of women with advanced/recurrent endometrial cancer.
DLBCL: Treatment Considerations in the Second Line
Experts on diffuse large B-cell lymphoma discuss the factors that inform their treatment choices in the second line.
Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.
The Future of Immunotherapy is ‘Bright’ in Multiple Myeloma
C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.
Selecting Patients with MM for Teclistamab and Optimal Sequencing
The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific Antibody
Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.
Managing Neurotoxicity Associated with Bispecifics in MM
A comprehensive discussion on managing neurotoxicity associated with bispecific antibodies in multiple myeloma.
